6978.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 10:08):

Stats
Dagens volum	22 000.00
Gjennomsnittsvolum	38 185.00
Markedsverdi	1.70B
EPS	HKD0 ( 2024-03-28 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.73
ATR14	HKD0 (0.00%)

Immunotech Biopharm Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Immunotech Biopharm Ltd Økonomi

Annual	2023
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-0.650

FY	2023
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-0.650

FY	2022
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-0.690

FY	2021
Omsetning:	HKD0.00
Bruttogevinst:	HKD0.00 (0.00 %)
EPS:	HKD-0.708

Financial Reports:

No articles found.

Immunotech Biopharm Ltd

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.